LI
AXSM icon

Leap Investments’s Axsome Therapeutics AXSM Stock Holding History

Leap Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$576K Buy
+7,000
New +$539K 0.38% 85
2019
Q4 		– Sell
-24,500
Closed -$496K – 430
2019
Q3 		$496K Buy
+24,500
New +$630K 0.25% 139

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Leap Investments's AXSM Position: Q2 2020 in Review

Leap Investments opened a new position in Axsome Therapeutics (AXSM) in Q2 2020: 7,000 shares worth $576K. The stake represents 0.38% of the portfolio and ranks #85 among its holdings. This is a return to the name: Leap Investments previously reported a position in AXSM as recently as Q3 2019.

Leap Investments first reported a position in AXSM in Q3 2019 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold AXSM as of Q2 2020.

  • Leap Investments held 7,000 shares of Axsome Therapeutics worth $576K as of Q2 2020.
  • Axsome Therapeutics was a new Leap Investments position in Q2 2020.
  • Axsome Therapeutics made up 0.38% of Leap Investments's portfolio in Q2 2020, its #85 holding.
  • Leap Investments first reported a position in Axsome Therapeutics in Q3 2019 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.